Monday, August 31, 2015

Cantor starts Affymetrix at buy

Cantor starts Affymetrix at buy

August 27, 2015 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Affymetrix (NASDAQ:AFFX) with a “buy’ rating and $13 target price. The stock closed at $8.83 on Wednesday. “Over the last four years, management has retooled its product portfolio, reorganized the business units, diversified away from gene expression, and returned the company to profitability,” writes analyst Bryan Brokmeier. “While […]

Cantor starts Pacific Biosciences at buy

Cantor starts Pacific Biosciences at buy

August 27, 2015 by · Leave a Comment 

Tweet Cantor Fitzgerald has initiated coverage of Pacific Biosciences of California (NASDAQ:PACB) with a “buy” rating and a 12-month target price of $9. The stock closed at $4.58 on Wednesday. Pacific is a pure-play sequencing company with an estimated 2% share of the $2.3-billion sequencing market. “In each of the last two years, Pacific has […]

Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

August 26, 2015 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly […]

Roth ups Sarepta Therapeutics price target to $50

Roth ups Sarepta Therapeutics price target to $50

August 26, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $50 from $45 after the FDA set Feb 26 as the PDUFA date to consider approval of the company’s NDA for eteplirsen. The stock closed at $32.58 on Tuesday. Eteplirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) amenable […]

Stifel starts vTv Therapeutics at buy

Stifel starts vTv Therapeutics at buy

August 24, 2015 by · Leave a Comment 

Tweet Stifel has initiated coverage of vTv Therapeutics (NASDAQ:VTVT) with a “buy” rating and $17 price target, pointing to its significant Alzheimer’s disease (AD) and diabetes assets. The stock closed at $8.85 on Friday. “Unlike many of its predecessors, the company remained private and in stealth mode for two decades before going public with three […]

Dipexium surpasses 50% treatment in Phase 3 trial

Dipexium surpasses 50% treatment in Phase 3 trial

August 20, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 Phase 3 clinical trial has passed the 50% enrolment milestone. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with 180 patients per trial, being conducted under a Special Protocol Assessment agreement with the FDA for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot […]

HCW starts Biocept at buy

HCW starts Biocept at buy

August 19, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and $4 price target. The stock closed at $1.96 on Tuesday. Biocept is a commercial-stage company in the emerging field of liquid biopsy, focusing on the capture, enumeration and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood […]

ROTH ups Titan Pharma price target to $1.50

ROTH ups Titan Pharma price target to $1.50

July 17, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on Titan Pharmaceuticals (OTCQB:TTNP) to $1.50 from $1.25. The stock closed at 80 cents on Thursday. Analyst Scott Henry writes that the driver for the increased price target is the positive Phase 3 data on Probuphine, which was reported last month. Probuphine is a six-month implant […]

HCW starts Nivalis Therapeutics at buy

HCW starts Nivalis Therapeutics at buy

July 13, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Nivalis Therapeutics (NASDAQ:NVLS) with a “buy” rating and $30 price target. The stock closed at $16.60 on Friday. “In line with the preclinical flags raised by independent academic labs since 2013, Orkambi’s pivotal readout in 2014 and its recent AdCom and approval reminded us that the combination of […]

Cynapsus launches public offering, applies to dual-list on NASDAQ

Cynapsus launches public offering, applies to dual-list on NASDAQ

June 10, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) is offering to sell 4.5 million common shares in an underwritten public offering through a registration statement filed with the SEC. BofA Merrill Lynch is acting as sole book-running manager for the proposed offering, with Nomura as a lead manager, and Noble Life Science Partners as co-manager. Cynapsus also expects […]

Next Page »

Email Newsletters with Constant Contact
Google+